Completed INTERVENTIONAL NCT04174716

Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS) (VASTUS)

An Open-label, Multi-center, Phase 1b/2a Basket Trial of IDX-1197 in Patients With Homologous Recombination Repair Mutated Solid Tumors

Sponsor: Idience Co., Ltd.

Conditions Homologous Recombination Deficiency Homologous Recombination Repair Gene Mutation Solid Tumors

Interventions IDX-1197

Updated 13 times since 2019 Last updated: Apr 14, 2026 Started: Nov 6, 2019 Primary completion: Mar 31, 2023 Completion: Jun 28, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Homologous Recombination Deficiency and Homologous Recombination Repair Gene Mutation and is currently completed. Idience Co., Ltd. leads this study, which shows 13 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

13 versions recorded

Apr 18, 2026 — Present [daily]

Completed

Phase: PHASE1/PHASE2 → None
Sep 2025 — Apr 2026 [monthly]

Completed PHASE1/PHASE2
Oct 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2

Status: Active Not Recruiting → Completed
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 8 earlier versions

Apr 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2022 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2
Dec 2021 — Feb 2022 [monthly]

Recruiting PHASE1_PHASE2
Mar 2021 — Dec 2021 [monthly]

Recruiting PHASE1_PHASE2
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1_PHASE2
Jul 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Dec 2019 — Jul 2020 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Nov 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

This study is a Phase 1b/2a basket trial to assess safety and efficacy of IDX-1197 in patients with HRR mutation. There are two parts to this study: Phase 1b, IDX-1197 dose-selection study to determine RP2D and Phase 2a, non-randomized parallel dose expansion study to confirm RP2D.

Contact Information

Sponsor contact:

Idience Co., Ltd.

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Busan, South Korea , Busan, South Korea , Busan, South Korea , Goyang, South Korea , Hwasun, South Korea , Incheon, South Korea , Jinju, South Korea , Seongnam-si, South Korea , Seongnam-si, South Korea , Seoul, South Korea and 9 more locations